Long-acting aripiprazole (depot) versus placebo for schizophrenia

To assess the efficacy and safety of long-acting aripiprazole (depot) compared with placebo for people with schizophrenia.

This is a protocol.

Health topics:

Mental health > Schizophrenia & psychosis > Antipsychotic medication: atypical

Published:

25 September 2016

Authors:

Hodgson RE, Belgamwar RB, Walsh S

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
Hodgson RE, Belgamwar RB, Walsh S. Long-acting aripiprazole (depot) versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2016, Issue 9. Art. No.: CD012360. DOI: 10.1002/14651858.CD012360